TIM-3表达与非小细胞肺癌预后及临床病理特征关系的meta分析  

Relationship between expression of TIM-3 and prognosis, clinicopathological features in non-small cell lung cancer: a meta-analysis

作　　者：谯钰琪 惠盼 董济民[2] 南岩东 Qiao Yuqi;Hui Pan;Dong Jimin;Nan Yandong(Department of Respiratory and Critical Care Medicine,Tangdu Hospital,Air Force Medical University,Xi'an 710038,China;Department of Oncology,Xi'an Central Hospital,Xi'an 710038,China)

机构地区：[1]空军军医大学唐都医院呼吸与危重症医学科,西安710038 [2]西安市中心医院肿瘤科,西安710038

出　　处：《国际呼吸杂志》2022年第21期1627-1634,共8页International Journal of Respiration

基　　金：陕西省社会发展科技攻关项目(2016SF-318);唐都医院创新发展基金(2017LCYJ016)。

摘　　要：目的探讨新兴免疫检查点相关分子T细胞免疫球蛋白黏蛋白3(TIM-3)的表达与非小细胞肺癌(NSCLC)患者预后及临床病理特征的相关性。方法计算机检索PubMed、Embase、Cochrane Library和Web of Science 4个英文数据库,以及中国生物医学文献数据库、中国知网、维普中文科技期刊数据库和万方数据知识服务平台4个中文数据库,检索时间为各个数据库自建库之日起至2022年3月1日。按照入排标准进行文献筛选后,采用Stata SE 12.0和RevMan 5.3软件进行meta分析。结果共纳入12篇文献、1788例NSCLC患者样本。meta分析结果显示TIM-3高表达是NSCLC患者总生存期(HR=2.06,95%CI:1.76~2.40,P<0.001)、无复发生存期(HR=2.43,95%CI:1.84~3.21,P<0.001)和无进展生存期(HR=2.19,95%CI:1.30~3.70,P=0.003)的不良预后因素;高表达的TIM-3与NSCLC患者淋巴结转移状态(OR=2.26,95%CI:1.51~3.39,P<0.001)、TNM分期(OR=2.13,95%CI:1.37~3.32,P<0.001)和PD-1表达状态(OR=3.78,95%CI:2.37~6.01,P<0.001)相关。结论TIM-3高表达的NSCLC患者较低表达的患者总生存期、无复发生存期和无进展生存期更短,并且高表达的TIM-3与较晚的TNM分期以及淋巴结转移阳性状态相关,提示TIM-3可能参与肿瘤进展,有望作为NSCLC预后不良的标志物和肺癌免疫治疗的关键分子靶点。Objective To explore the relationship between the expression of T cell immunoglobulin mucin-3(TIM-3),a novel molecular-related immune checkpoint,and prognosis,clinicopathological features in patients with non-small cell lung cancer(NSCLC).Methods Four English databases including PubMed,Embase,Cochrane Library and Web of Science as well as four Chinese databases involving CBM,CNKI,VIP database and Wanfang database were subjected to computer retrieval by ranging from the date of establishment to March 1,2022.A meta-analysis was performed by Stata SE 12.0 and RevMan 5.3 software after literature screening based on the inclusion and exclusion criteria.Results A total of 12 literatures representing 1788 NSCLC patient samples were included in analysis.Meta analysis results showed that high expression of TIM-3 was a poor prognostic factor for overall survival(OS)(HR=2.06,95%CI:1.76-2.40,P<0.001),recurrence-free survival(RFS)(HR=2.43,95%CI:1.84-3.21,P<0.001)and progression-free survival(PFS)(HR=2.19,95%CI:1.30-3.70,P=0.003)of NSCLC patients.Highly expressed TIM-3 was correlated with lymph node metastasis status(OR=2.26,95%CI:1.51-3.39,P<0.001),TNM stage(OR=2.13,95%CI:1.37-3.32,P<0.001)and expression status of PD-1(OR=3.78,95%CI:2.37-6.01,P<0.001)of NSCLC patients.Conclusions The OS,RFS and PFS of NSCLC patients with highly expressed TIM-3 are lower than those with lowly expresed TIM-3,and highly expressed TIM-3 is associated with later TNM stage and positive status of lymph node metastasis,indicating TIM-3 may be involved in the tumor progression and may serve as a biomarker for poor prognosis in NSCLC and a key molecular target for imunotherapy of lung cancer.

关 键 词：癌 非小细胞肺 META分析 预后 T细胞免疫球蛋白黏蛋白3 

分 类 号：R734.2[医药卫生—肿瘤]